Miltenyi Biotec: Market Success for Cell and Gene Therapies – Solving The Challenges Of Taking Novel Cellular Therapies To Commercial Scale
Wednesday, May 29, 2024 03:00 PM - 04:30 PM
Room 211
Corporate Session
Chair
Session Objectives
- Ian Gaudet, PhD, Chief Scientific Director, Miltenyi Bioindustry
- Matthew Hewitt, PhD, Vice President, Technical Officer for CGT, Charles River Laboratories, United States
- David Brochu, PhD, Chef Technology Officer, CTO, Autolus Limited
- Tony Barnitz, PhD, Director, Manufacturing Sciences and Technologies (MSAT) Adaptimmune
Session Objectives
- Current methods for commercial scale development, manufacturing and analytical testing
- Challenges and solving strategies for obtaining approval for CGT products young biotech companies face
- How next-gen innovations and technology platforms contribute to scalability, consistency and cost-effectiveness
- Evaluating factors that influence strategic decisions to manufacture CGTs in-house versus outsourcing to CMOs
SPONSORED BY:
